{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T12:44:27Z","timestamp":1776170667901,"version":"3.50.1"},"reference-count":35,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Multiple myeloma (MM), a clonal plasma cell malignancy, remains incurable despite significant therapeutic advances, including novel immunotherapies like chimeric antigen receptor T\u2010cell (CAR\u2010T) therapy and bispecific antibodies. This perspective reevaluates the concept of \u201ccure\u201d in MM, challenging the traditional binary definition of complete disease eradication. The author proposes a dynamic, patient\u2010centric model integrating sustained minimal residual disease (MRD) negativity, functional cure, and quality of life (QoL) to align clinical goals with biological realities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This perspective reviews current literature on MM pathophysiology, focusing on intratumoral heterogeneity and bone marrow microenvironment interactions as drivers of therapeutic resistance. It critiques existing cytotoxic and immunomodulatory paradigms and explores emerging strategies, including precision medicine, single\u2010cell genomics, and artificial intelligence (AI)\u2010driven risk stratification, to redefine therapeutic endpoints.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Novel immunotherapies achieve deep responses, with MRD negativity rates approaching 80% in some cohorts; however, relapse remains a significant challenge due to subclonal evolution and dormant MM clones. Current treatment paradigms fail to fully address these biological complexities, necessitating innovative approaches that combine therapies, target resistant clones, and incorporate patient\u2010reported outcomes to balance efficacy with QoL.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Reframing cure as a spectrum rather than an absolute state offers a more realistic framework for MM management. By leveraging precision medicine and integrating QoL considerations, clinicians and researchers can foster durable remissions and improve patient outcomes. This perspective advocates for a paradigm shift, urging the MM community to embrace biological complexity and redefine success in this evolving therapeutic landscape.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.71581","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T06:31:21Z","timestamp":1764225081000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Redefining Cure in Multiple Myeloma: Are We Chasing a Moving Target?"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1184-9029","authenticated-orcid":false,"given":"Jacob Henry","family":"Kitundu","sequence":"first","affiliation":[{"name":"Department of Internal Medicine Kilimanjaro Christian Medical Centre (KCMC) Moshi Tanzania"},{"name":"Department of Internal Medicine Eagle Hospital Manyara Tanzania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_2_13_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/157496"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0196-8"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00437"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12233"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-025-06241-0"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21177-5"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006731"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01012-4"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611750"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283058"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06143-7"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000395"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01488-8"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-496"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.222299"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0396"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606038"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00208-8"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-147983"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024014232"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00657-1"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2204591"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209900"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-151195"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-20-0227"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185151"},{"key":"e_1_2_13_36_1","unstructured":"Multiple Myeloma Research Consortium (MMRC) \u201cHorizon One: A Phase 2 Platform Study of Novel Combinations in Relapsed or Refractory Multiple Myeloma \u201d ClinTrials.gov published 2024 Identifier: NCT06171685 https:\/\/clinicaltrials.gov\/study\/NCT06171685."}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.71581","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/hsr2.71581","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.71581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T11:48:14Z","timestamp":1776167294000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.71581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":35,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/hsr2.71581"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.71581","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]},"assertion":[{"value":"2025-04-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71581"}}